英国国家卫生与临床优化研究所（NICE）基于价值的卫生技术评估的近期修订：是否存在隐性不公平？ - Suppr

Suppr

超能文献

Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?

作者信息

Paulden Mike

机构信息

a School of Public Health , University of Alberta , Edmonton , Canada.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):239-242. doi: 10.1080/14737167.2017.1330152. Epub 2017 May 23.

DOI:10.1080/14737167.2017.1330152

PMID:28490259

Abstract

摘要

相似文献

Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?英国国家卫生与临床优化研究所（NICE）基于价值的卫生技术评估的近期修订：是否存在隐性不公平？

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):239-242. doi: 10.1080/14737167.2017.1330152. Epub 2017 May 23.

Some inconsistencies in NICE's consideration of social values.英国国家卫生与临床优化研究所（NICE）在社会价值观考量方面存在一些不一致之处。

Pharmacoeconomics. 2014 Nov;32(11):1043-53. doi: 10.1007/s40273-014-0204-4.

NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.NICE 有选择地应用差别折扣：模糊、不一致且没有正当理由。

Value Health. 2014 Jul;17(5):493-6. doi: 10.1016/j.jval.2013.02.014. Epub 2013 May 15.

Is there an alternative to quality-adjusted life years for supporting healthcare decision making?在支持医疗保健决策方面，是否存在质量调整生命年的替代方法？

Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):351-7. doi: 10.1080/14737167.2016.1184975.

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.通过 NICE 的单一技术评估途径评估罕见病技术的灵活性：主题分析。

J Comp Eff Res. 2023 Nov;12(11):e230093. doi: 10.57264/cer-2023-0093. Epub 2023 Sep 19.

Evidence-based decision-making 3: Health technology assessment.循证决策3：卫生技术评估。

Methods Mol Biol. 2015;1281:417-41. doi: 10.1007/978-1-4939-2428-8_25.

DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.NICE 技术评估框架的决策组成部分。

Int J Technol Assess Health Care. 2018 Jan;34(2):163-171. doi: 10.1017/S0266462318000090. Epub 2018 Apr 10.

Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.英国国家卫生与临床优化研究所对医疗技术的评估：关于在卫生技术评估中更好纳入治疗价值的建议

Health Econ. 2010 Oct;19(10):1109-16. doi: 10.1002/hec.1654.

Why it's Time to Abandon the ICER.为何是时候摒弃成本效果分析（ICER）了。

Pharmacoeconomics. 2020 Aug;38(8):781-784. doi: 10.1007/s40273-020-00915-5.

Modifying NICE's Approach to Equity Weighting.修改 NICE 的公平加权方法。

Pharmacoeconomics. 2021 Feb;39(2):147-160. doi: 10.1007/s40273-020-00988-2. Epub 2021 Jan 31.

引用本文的文献

Considerations when applying equity weights within economic evaluation when making drug reimbursement decisions.在做出药品报销决策时，在经济评估中应用公平权重时的考量因素。

Health Econ Rev. 2024 Nov 13;14(1):90. doi: 10.1186/s13561-024-00556-w.

Framework for developing cost-effectiveness analysis threshold: the case of Egypt.制定成本效益分析阈值的框架：以埃及为例。

J Egypt Public Health Assoc. 2024 Jun 3;99(1):12. doi: 10.1186/s42506-024-00159-7.

A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries.一项关于直接 elicitation 需求方成本效益阈值的系统评价：对低收入和中等收入国家的启示。

PLoS One. 2024 Feb 8;19(2):e0297450. doi: 10.1371/journal.pone.0297450. eCollection 2024.

Establishing cost-effectiveness threshold in China: a community survey of willingness to pay for a healthylife year.在中国建立成本效益阈值：一项关于健康生活年支付意愿的社区调查。

BMJ Glob Health. 2024 Jan 9;9(1):e013070. doi: 10.1136/bmjgh-2023-013070.

Valuing infertility treatment: Why QALYs are inadequate, and an alternative approach to cost-effectiveness thresholds.重视不孕治疗：为何质量调整生命年（QALYs）并不充分，以及成本效益阈值的替代方法。

Front Med Technol. 2022 Dec 23;4:1053719. doi: 10.3389/fmedt.2022.1053719. eCollection 2022.

What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand.提高成本效益阈值的影响是什么？一项基于泰国进行的经济评估的实证研究的方案。

PLoS One. 2022 Oct 3;17(10):e0274944. doi: 10.1371/journal.pone.0274944. eCollection 2022.

Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.卫生技术评估组织在确定药品价格时会考虑制造商的成本吗？一项关于报销报告的研究。

Cost Eff Resour Alloc. 2022 Aug 31;20(1):46. doi: 10.1186/s12962-022-00383-y.

Mapping analysis to predict the associated EuroQol five-dimension three-level utility values from the Oxford Knee Score : a prediction and validation study.映射分析以根据牛津膝关节评分预测相关的欧洲五维健康量表三级效用值：一项预测与验证研究

Bone Jt Open. 2022 Jul;3(7):573-581. doi: 10.1302/2633-1462.37.BJO-2022-0054.R1.

Comparable worth of life for all? Conducting and disseminating health economic evaluations for refugees in Germany.所有人的生命都有同等价值吗？在德国对难民进行和传播卫生经济评估。

Global Health. 2022 May 12;18(1):48. doi: 10.1186/s12992-022-00845-1.

Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.决策规则在成本效益分析中的可负担性和价值：对卫生经济学家的调查。

Value Health. 2022 Jul;25(7):1141-1147. doi: 10.1016/j.jval.2021.11.1375. Epub 2022 Feb 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验